Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOVUNA vs ARALEN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SOVUNA (suvorexant) is a dual orexin receptor antagonist that blocks the binding of orexin neuropeptides to orexin OX1 and OX2 receptors, thereby promoting sleep initiation and maintenance.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.
FDA-approved for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Treatment of uncomplicated malaria due to chloroquine-sensitive Plasmodium species,Prophylaxis of malaria in areas with chloroquine-sensitive parasites,Extraintestinal amebiasis,Treatment of discoid lupus erythematosus (off-label),Treatment of rheumatoid arthritis (off-label)
400 mg orally once daily with food.
Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.
Terminal half-life 14 hours; clinically significant for once-daily dosing, requiring dose adjustment in renal impairment (Cr Cl <30 m L/min).
48-72 hours (terminal elimination half-life); prolonged to weeks with chronic dosing due to extensive tissue accumulation, especially in the liver, spleen, and melanin-containing tissues.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19; undergoes oxidative metabolism to form hydroxy and carboxylic acid metabolites.
Hepatic metabolism via CYP2C8, CYP3A4, and CYP2D6 to desethylchloroquine and other metabolites.
Primarily renal (70% unchanged) and 20% fecal via bile; minor metabolic clearance.
Renal (~70% unchanged), with 10-20% in feces; biliary elimination is minor.
98% bound to albumin.
50-60%, primarily to albumin and α1-acid glycoprotein.
0.15 L/kg; indicates limited extravascular distribution, consistent with high plasma protein binding.
50-100 L/kg; extensive tissue sequestration including erythrocytes, liver, spleen, and melanin-containing tissues like skin and retina.
Oral: 85%.
Oral: ~70-80% (variable due to first-pass metabolism); intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
Severe renal impairment (GFR <10 m L/min): reduce dose by 50% or increase dosing interval.
Child-Pugh A: No adjustment. Child-Pugh B: 200 mg orally once daily. Child-Pugh C: Not recommended.
Use with caution in patients with hepatic impairment; no specific dose adjustment guidelines available; contraindicated in severe hepatic disease or porphyria.
Weight-based: ≥40 kg: 400 mg orally once daily; <40 kg: Not approved.
Prophylaxis: 5 mg base/kg orally once weekly (max 300 mg base). Treatment: 10 mg base/kg orally initially, then 5 mg base/kg at 6, 24, and 48 hours (max 600 mg base total).
No specific dose adjustment; monitor renal function due to age-related decline.
Start at lower end of dosing range due to increased risk of adverse effects (e.g., QT prolongation, retinal toxicity); monitor renal function.
None.
No FDA black box warning.
Potential for next-day impairment (e.g., drowsiness, impaired driving), risk of CNS depression, complex sleep behaviors (e.g., sleep-driving), risk of worsening depression or suicidal thoughts, caution in patients with a history of substance abuse.
Retinopathy and irreversible retinal damage with prolonged use or high doses; requires baseline and periodic ophthalmologic exams,QT prolongation and ventricular arrhythmias, especially with concomitant QT-prolonging drugs or electrolyte abnormalities,Severe hypoglycemia including loss of consciousness,Neuropsychiatric effects including psychosis and suicidal ideation,Hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency
Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) or strong CYP3A4 inducers (e.g., rifampin); patients with narcolepsy.
Hypersensitivity to chloroquine or any 4-aminoquinoline,Pre-existing retinopathy or known maculopathy,Known G6PD deficiency (relative, use with caution),Concomitant use with strong QT-prolonging drugs (e.g., quinidine, procainamide)
Avoid grapefruit and grapefruit juice; take with or without food but consistently.
Avoid grapefruit and grapefruit juice as they may increase drug levels and toxicity. Limit alcohol intake to reduce risk of liver toxicity. Administer with food to decrease gastrointestinal irritation. Avoid antacids containing aluminum or magnesium; separate by at least 4 hours.
Based on animal studies, SOVUNA (antiviral agent) is associated with increased fetal loss and skeletal anomalies at maternal toxic doses in rodents and rabbits. In humans, data are insufficient to define a precise teratogenic risk. First trimester exposure does not show a clear pattern of major congenital malformations, but potential risks cannot be excluded. Second and third trimester exposure: no specific fetal adverse effects reported in limited human studies, but caution is advised due to possible placental transfer and unknown fetal effects.
Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) at high doses. Second and third trimesters: possible ototoxicity and retinal toxicity; use only for malaria prophylaxis or treatment when benefit outweighs risk.
It is not known whether SOVUNA is excreted in human breast milk. Animal studies show excretion in milk. Due to potential adverse effects in nursing infants, breastfeeding during treatment is not recommended. M/P ratio is unknown.
Chloroquine is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Amounts are unlikely to cause adverse effects in nursing infants. The American Academy of Pediatrics considers chloroquine compatible with breastfeeding. Monitor infant for potential ocular effects.
No specific dosing adjustments are required during pregnancy based on available pharmacokinetic data. However, due to physiological changes in pregnancy (e.g., increased plasma volume, altered hepatic metabolism), monitoring of clinical response and tolerance is recommended. No dose adjustment is recommended for standard antiviral dosing.
Increased volume of distribution and clearance during pregnancy may require higher doses for malaria prophylaxis (e.g., 400 mg base weekly) and treatment; therapeutic drug monitoring recommended for optimal dosing. No standard dose adjustment established; base dose on indication and clinical response.
Monitor hepatic function closely due to potential hepatotoxicity; assess renal function before initiation; avoid in patients with severe hepatic impairment (Child-Pugh C).
ARALEN HYDROCHLORIDE (chloroquine hydrochloride) is used for malaria prophylaxis and treatment, and for amebiasis. Monitor for retinal toxicity with long-term use; baseline and periodic ophthalmologic exams recommended. Caution in patients with hepatic disease, G6PD deficiency, or porphyria. May exacerbate psoriasis and myasthenia gravis. QT prolongation possible; avoid with other QT-prolonging drugs. Administer with food to reduce GI upset. For acute malaria, dose may be divided to improve tolerance. In severe malaria, use parenteral form with cardiac monitoring.
Take exactly as prescribed; do not stop without consulting your doctor.,Report any signs of liver problems: yellowing skin/eyes, dark urine, severe abdominal pain.,Avoid alcohol completely while on this medication.,If you miss a dose, take it as soon as you remember unless it's almost time for next dose; do not double dose.,Use effective contraception during treatment and for 30 days after stopping.
Take this medication exactly as prescribed; do not skip doses for malaria prophylaxis.,If vomiting occurs within 1 hour of a dose, contact your healthcare provider for instructions.,Report any vision changes, such as blurred vision or difficulty focusing, immediately.,Avoid alcohol and limit caffeine intake as they may increase gastrointestinal side effects.,Use effective contraception during treatment if you are of childbearing potential.,Do not take antacids or kaolin within 4 hours of this medication.,Seek medical attention if you experience signs of allergic reaction: rash, hives, swelling, or difficulty breathing.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOVUNA vs ARALEN HYDROCHLORIDE, answered by our medical review team.
SOVUNA is a Antimalarial that works by SOVUNA (suvorexant) is a dual orexin receptor antagonist that blocks the binding of orexin neuropeptides to orexin OX1 and OX2 receptors, thereby promoting sleep initiation and maintenance.. ARALEN HYDROCHLORIDE is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOVUNA and ARALEN HYDROCHLORIDE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOVUNA is: 400 mg orally once daily with food.. The standard adult dose of ARALEN HYDROCHLORIDE is: Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOVUNA and ARALEN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOVUNA is classified as Category C. Based on animal studies, SOVUNA (antiviral agent) is associated with increased fetal loss and skeletal anomalies at maternal toxic doses in rodents and rabbits. In humans, data are. ARALEN HYDROCHLORIDE is classified as Category C. Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.